Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience
Haemophilia · 2024
DOI: 10.1111/hae.15007 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Haemophilia, 2024. Verfasst von Radha Ramanan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hemophilia A, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
To characterise non‐severe haemophilia A (HA) patients enrolled on the Australian Bleeding Disorders Registry (ABDR) treated through a state‐wide Haemophilia Treatment Centre (HTC) with respect to their mutational profile, inhibitor risk and health‐care burden.
Method
We conducted a single‐centre observational study of all non‐severe HA patients treated at the Alfred Health HTC registered on the ABDR as of the 26th July 2023. Data were extracted from the ABDR and electronic medical record (EMR) regarding demographics, severity, genetic testing, treatment, inhibitors, bleeding events and procedures. Inhibitor risk was calculated as a function of exposure days (EDs) of FVIII replacement.
Results
There were 289 non‐severe HA patients treated at the Alfred HTC registered on the ABDR as of July 2023, all of whom were adult patients aged > 18 years old. Genotyping had been performed in 228/289 (78.9%). Of the inhibitor analysis population, 14/193 (7.3%) had an inhibitor. The cumulative incidence of inhibitor development at 75 EDs was 31% (95% CI 13%–46%). The median cost of bypassing agents per inhibitor patient was $57,087.50/year.
Conclusion
These results demonstrate a relatively high inhibitor prevalence and incidence risk in non‐severe HA compared to previously published work, although this may partly reflect a smaller population size. High rates of genotyping have allowed representative mutational characterisation. The burden of care imposed by non‐severe HA in terms of bleeding events, procedures and bypassing agent cost is larger than expected, particularly within the inhibitor population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
- Ronald Sawers Haemophilia Treatment Centre, Department of Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
- Australian Haemophilia Centre Directors' Organisation, Melbourne, Victoria, Australia.
- Department of Clinical Haematology, Monash Health, Melbourne, Victoria, Australia.
ORCID-Profile: Radha Ramanan
Zitieren
APA
Ramanan, R., Evans, N., Kaplan, Z., McFadyen, J. D., & Tran, H. A. (2024). Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience. Haemophilia. https://doi.org/10.1111/hae.15007
Vancouver
Ramanan R, Evans N, Kaplan Z, McFadyen JD, Tran HA. Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience. Haemophilia. 2024. doi:10.1111/hae.15007
BibTeX
@article{Ramanan2024,
author = {Ramanan, Radha and Evans, Natalie and Kaplan, Zane and McFadyen, James D and Tran, Huyen A},
title = {Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15007}
}
EUVIMED